Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals ( ($APLS) ) has issued an update. On March 31, 2026, Apellis Pharmaceuticals agreed to be acquired by Biogen through a tend...

Apellis Pharmaceuticals to be Acquired by Biogen in Merger

The latest stock market stories for Tuesday are ready to go in the daily wrap-up.


Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!

Analysts fell to the sidelines weighing in on Alkermes (ALKS), Apellis Pharmaceuticals (APLS) and Kalaris Therapeutics (KLRS) with neutral ratings,...

Wall Street Analysts Are Neutral on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research Report) and...

Market Cap	$5.20B	P/E Ratio	N/A
52W High	$40.48	52W Low	$16.10
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	43.4%	52W Position	100.9%
Overall Score	38	Value Score	35
Quality Score	63	Technical Score	16

EPS Current Est	$-1.26	EPS Next Est	$-0.52
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APLS	$40.70	0.00%	3.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APLS	$40.70	0%	3.23M
3
4
5
6

APLS

APLS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Apellis Pharmaceuticals Inc. Data in Excel

Get Apellis Pharmaceuticals Inc. Data in Excel